# GDI2

## Overview
GDI2, or GDP dissociation inhibitor 2, is a gene that encodes a regulatory protein involved in the modulation of Rab GTPases, which are critical for intracellular membrane trafficking. The GDI2 protein functions as a GDP dissociation inhibitor, maintaining Rab proteins in their inactive GDP-bound state within the cytosol, thereby facilitating their recycling and ensuring efficient vesicular transport processes (Shisheva1999General). As a member of the GDP dissociation inhibitor family, GDI2 shares significant sequence similarity with other isoforms, such as GDI-1, and can compensate for their absence in certain contexts (Shisheva1999General). The protein's activity is modulated by post-translational modifications, such as tyrosine phosphorylation, which enhance its interaction with specific Rab proteins (Shisheva1999General). Clinically, alterations in GDI2 expression have been linked to cancer progression, with its reduced expression associated with increased metastatic potential in bladder cancer, while higher expression correlates with improved outcomes in colorectal carcinoma (Fujita2011Clinical; Theodorescu2004Reduced).

## Structure
The GDI2 protein, also known as GDP dissociation inhibitor 2, is involved in the regulation of Rab proteins, which are small GTP-binding proteins crucial for membrane trafficking. The primary structure of GDI2 consists of 445 amino acids, with a deduced molecular weight of approximately 50,649 Da (Shisheva1994Cloning). The protein shares a high sequence identity with other GDI isoforms, such as GDI-1, with an 86% similarity (Shisheva1994Cloning).

The secondary structure of GDI2 likely includes alpha helices and beta sheets, typical of proteins involved in binding interactions, although specific details are not provided in the context. The tertiary structure forms a compact, globular shape, which is essential for its function in binding and solubilizing Rab proteins from membranes (Shisheva1999General).

GDI2 can undergo post-translational modifications, such as tyrosine phosphorylation, which can enhance its interaction with specific Rab proteins, like Rab4 (Shisheva1999General). This modification suggests a regulatory mechanism for GDI2's activity in vivo. The protein may also exist in different isoforms due to alternative splicing, although specific isoforms are not detailed in the context provided.

## Function
GDI2 (GDP dissociation inhibitor 2) plays a crucial role in the regulation of Rab proteins, which are essential for intracellular membrane trafficking. GDI2 facilitates the solubilization and membrane release of various Rab proteins, including Rab2, Rab4, Rab5, Rab8, Rab9, and Rab11, by binding to them and maintaining them in an inactive GDP-bound state in the cytosol (Shisheva1999General). This process is vital for the recycling of Rab proteins, allowing them to participate in multiple rounds of vesicular transport (Shisheva1999General).

GDI2 is predominantly active in the cytosol and is involved in maintaining intracellular membrane trafficking by facilitating the return of Rab proteins from membranes to the cytosol (Shisheva1999General). It can compensate for the absence of GDI-1, as evidenced by its ability to take over functions in humans with GDI-1 mutations (Shisheva1999General). Structural modifications, such as tyrosine phosphorylation, can enhance GDI2's interactions with specific Rab proteins, indicating that posttranslational modifications play a role in its functional activity (Shisheva1999General). GDI2's activity is crucial for processes like endocytosis and exocytosis, impacting cellular and organismal functions.

## Clinical Significance
Alterations in the expression of the GDI2 gene, also known as RhoGDI2, have significant clinical implications, particularly in cancer. In bladder cancer, reduced expression of RhoGDI2 is associated with increased metastatic potential and poorer clinical outcomes. Studies have shown that low levels of RhoGDI2 correlate with decreased disease-free and disease-specific survival rates in bladder cancer patients, suggesting its role as a prognostic marker (Theodorescu2004Reduced). Reexpression of RhoGDI2 in metastatic bladder cancer cell lines has been shown to inhibit metastasis, particularly to the lungs, by suppressing the expression of genes like versican and endothelin-1, which are involved in cancer progression (Said2012RhoGDI2; Titus2005Endothelin).

In colorectal carcinoma, higher expression of RhoGDI2 is linked to a lack of liver metastasis and improved relapse-free survival, indicating its potential as a metastasis suppressor in this cancer type as well (Fujita2011Clinical). The gene's role in regulating Rho GTPases, particularly Rac1, is crucial for its function in metastasis suppression, although it operates through mechanisms distinct from the classic inhibition of Rho GTPase function (Moissoglu2009Rho).

## Interactions
GDP dissociation inhibitor 2 (GDI2) interacts with various Rab proteins, which are small GTPases involved in membrane trafficking. GDI2 plays a crucial role in the solubilization and membrane release of Rab proteins, including Rab2, Rab4, Rab5, Rab8, Rab9, and Rab11. It binds to the GDP-bound forms of these proteins, preventing their activation and maintaining them in an inactive state (Shisheva1999General).

Mutations in GDI2 can modulate its interactions with Rab proteins. For instance, the Y249V mutation enhances GDI2's ability to retrieve Rab9 from membranes, while the M250Y mutation significantly disrupts its interaction with GDP-loaded Rabs, highlighting the importance of specific residues in GDI2 for its functional interactions (Shisheva1999General).

GDI2 can also undergo tyrosine phosphorylation, which enhances its interaction with Rab4. This modification suggests that GDI2 can adopt a conformation with higher affinity for certain Rab proteins, potentially altering its functional interactions in vivo (Shisheva1999General). These interactions underscore GDI2's role in regulating Rab protein activity and membrane trafficking processes.


## References


[1. (Fujita2011Clinical) Akihiko Fujita, Atsuo Shida, Shuichi Fujioka, Hideaki Kurihara, Tomoyoshi Okamoto, and Katsuhiko Yanaga. Clinical significance of rho gdp dissociation inhibitor 2 in colorectal carcinoma. International Journal of Clinical Oncology, 17(2):137–142, June 2011. URL: http://dx.doi.org/10.1007/s10147-011-0270-y, doi:10.1007/s10147-011-0270-y. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s10147-011-0270-y)

[2. (Shisheva1999General) Assia Shisheva, Sreenivasa R. Chinni, and Carmen DeMarco. General role of gdp dissociation inhibitor 2 in membrane release of rab proteins: modulations of its functional interactions by in vitro and in vivo structural modifications. Biochemistry, 38(36):11711–11721, August 1999. URL: http://dx.doi.org/10.1021/bi990200r, doi:10.1021/bi990200r. This article has 40 citations and is from a peer-reviewed journal.](https://doi.org/10.1021/bi990200r)

[3. (Titus2005Endothelin) Brian Titus, Henry F. Frierson, Mark Conaway, Keith Ching, Theresa Guise, John Chirgwin, Garret Hampton, and Dan Theodorescu. Endothelin axis is a target of the lung metastasis suppressor gene rhogdi2. Cancer Research, 65(16):7320–7327, August 2005. URL: http://dx.doi.org/10.1158/0008-5472.can-05-1403, doi:10.1158/0008-5472.can-05-1403. This article has 89 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/0008-5472.can-05-1403)

[4. (Shisheva1994Cloning) Assia Shisheva, Thomas C. Südhof, and Michael P. Czech. Cloning, characterization, and expression of a novel gdp dissociation inhibitor isoform from skeletal muscle. Molecular and Cellular Biology, 14(5):3459–3468, May 1994. URL: http://dx.doi.org/10.1128/mcb.14.5.3459-3468.1994, doi:10.1128/mcb.14.5.3459-3468.1994. This article has 1 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.14.5.3459-3468.1994)

[5. (Moissoglu2009Rho) Konstadinos Moissoglu, Kevin S. McRoberts, Jeremy A. Meier, Dan Theodorescu, and Martin A. Schwartz. Rho gdp dissociation inhibitor 2 suppresses metastasis via unconventional regulation of rhogtpases. Cancer Research, 69(7):2838–2844, April 2009. URL: http://dx.doi.org/10.1158/0008-5472.can-08-1397, doi:10.1158/0008-5472.can-08-1397. This article has 57 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/0008-5472.can-08-1397)

[6. (Said2012RhoGDI2) Neveen Said, Marta Sanchez-Carbayo, Steven C. Smith, and Dan Theodorescu. Rhogdi2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration. Journal of Clinical Investigation, 122(4):1503–1518, April 2012. URL: http://dx.doi.org/10.1172/jci61392, doi:10.1172/jci61392. This article has 118 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci61392)

[7. (Theodorescu2004Reduced) Dan Theodorescu, L. M. Sapinoso, M. R. Conaway, G. Oxford, G. M. Hampton, and H. F. Frierson. Reduced expression of metastasis suppressor rhogdi2 is associated with decreased survival for patients with bladder cancer. Clinical Cancer Research, 10(11):3800–3806, June 2004. URL: http://dx.doi.org/10.1158/1078-0432.ccr-03-0653, doi:10.1158/1078-0432.ccr-03-0653. This article has 132 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/1078-0432.ccr-03-0653)